Systemic Bactericidal Complement in Human Cardiomyopathies: Revisiting Approach
DOI:
https://doi.org/10.14738/bjhr.1302.20284Keywords:
Blood, bactericidal effect, cardiac disease cardiomyopathy, complement, hypo-activityAbstract
Cardiac diseases are of common prevalence among age human beings. In a clinical setting, the cardiologist of working team at Hilla Mergan Teaching Hospital, diagnose 23 cardiomyopathy test patients whom complained inflammatory-infectious manifestations in continuum with ageing processes. Five normal aged and five normal adulthood were the controls. The test and control groups were enrolled in blood collection with heparin for bactericidal assay. The heparinized one in tenth diluted blood samples were inoculated with fresh diluted E coli culture suspensions. The inoculated blood samples were incubated for 10,20 and 40 minutes at 37C.Then streaked onto nutrient agar plates and incubated for an overnight period in 37C.To score bactericidal activity onto the streak line; confluent growth means no action, weak growth means hypoactive and no growth means active bactericidal complement. Complement bactericidal activity patterns in cardiomyopathy patients were as; inactive ,hypoactive and active. The nature of this bactericidal activity was found to be dependent on the initial blood-bacteria interaction time at 37C as the time passed from 10 to 40 min. Nine out of the 23(39.13%) test patient have shown inactivity up to 40 min incubation. Fourteen out of the 23(60.7%) were expressing various grades of bactericidal activity. Complement inactivity can be attributed to; consumption of complement in immune-pathogenesis of the cardiac disease, ageing and/ or infection induced complement suppressive effects. Complement hypoactivity may be due to the cardiomyopathy and /or ageing.
References
West,E.E.;Kemper,C.2023.Complosome-Intreacellular complement system. Nat. Rev. Nephrol.19,426-439.
Mathern,D.R.;Heeger,P.S.2015.Molecules great and small,Clin.J.Am.Nephrol .10(9):1636-1650.doi.10.2215/CJN.062306.
Shnawa,I.M.S.2014.Immunology.Ishtar&Dijla, Publishers,Iraq-Jordan[Arabic],30-40.
Sarma,J.V.;Ward,P.A.2010.The complement System.Cell Tissue Res.343(1):227-235.doi.10.1007/s0041-010-1034-0.
Sherman,S.K.;Collard,C.D.2001.Role of the complement system in ischeamic heart disease;potentials fo pharmacological intervention.Biodrug15(9):595-607.doi.2165/00063030-2001.15090-00004.
lappegard K.T.;Garred ,P.;Jonasson,L.et.al.2014.A vital role for complement in heart disease.Mol.Immunol.61(2):126-134.doi.10.1016/j.molimm.2014.06.036.
Chiorescu,R.M.;Mocan,M.;Iacobescu,M.et al.2025.Behavior of complement system effectors in chronic and acute coronary artery disease.JCM14(11):1-30.doi.10.3390/jcm14113947.
Kong,Y.;Wang,N.;Tong,Z.et.al.2024.Role of complement factor D in cardiovascular diseases. Front.Immunol.15:1453030.doi. 10.3389/fimmu 2024.1453030.
Wardlow,A.C.1982.Bactericidal activity of human blood.In,Primose,S.B. ed.Sourcebook of Experiments for Teaching of Microbiology,Academic Press ,paris,493-496.
Shnawa,I.M.S.;Mohammed M.Abdul-Razak,Al-Ameidi,B.H.H.1999.The bacteriolytic complement and immune-senescence .Bay.Uni.J.Pure.Appl.Sci.4(3):485-488.
Barbara J. ;Bates ,I.2016.Dacie and Lewis. Practical Hematology,12th ed .ElSevier.
Muri,L.;Schubart,A.;Thorburn,C.et.al.2022.Inhibition of different complement pathways has varying impacts on the serum bactericidal activity and opsonopha-gocytosis against Haemophilus influenza type b.Front.Immuol.13:1020580.doi .103389 /fimmu.2022.1020580.
Sarikonada,G.;von Herrath,M.G.2010.Immunosuppressive mechanisms during viral infectious diseases.Meth.Mol.Biol.667:431-447.doi.10.1007/978-1-60761-869-027.
Clark ,D.J.;Cleman,M.W.;Pfau,S.E.2001.Serum complement in congestive heart failure. Am. Heart J.141(4):684-690.doi.1967/mhi.2001.113758.
Zwaka ,T.P.;Manolova,D.;Ozdemir,C.et.al.2002.Complement and dilated cardiomyopathy;a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes.Am.J.Pathol.161(2):449-457.doi.10.1016/s0002-9440(10)64201-0.
Perkovic ,V.;Barratt,J.;Rovin,B.et.al.2024.Alternative pathway inhibition with Iptacopan in IgA nephropathy.N.E.J.Med.392(6):531-543.doi.10.1056 /NEJMoa 2410316.
Zhao,D.Wang,Y.;Wong,N.D.et.al.2024.Impact of ageing on cardiovascular diseases: from chronological observation to biological insight.FamilySeries. JACC.Asia.4(5):345-358.
Zhou,M.;Zhao,G.;Zeng ,Y.et.al.2022.Ageing and cardiovascular disease; Current status and Challenges.Rev.Cardiovasc.Med.23(4):135.doi.j.rcm234135.
Fattahi,F.;Ward,P.A.2016.Complement and sepsis-induced heart dysfunction. Mol.Immunol.84:57-64.doi.10.1016/jmolimm.2016.11.012.
Hok,K.D.;Rich,H.E.;Shadid,A.et.al.2025.Functional role of the complement immune system in cardiac inflammation and hyperatrophy. Int.J.Mol.Sci.26(20),9931.doi.10.3390/ijms.26209931.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ibrahim M S Shnawa, Mohamed M Abdurazak, Baha H H Alameidi

This work is licensed under a Creative Commons Attribution 4.0 International License.